Kangjia Tao
1095 Jiefang Ave
Wuhan, 430030, China
Wuhan, 430030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer.
Journal: Science translational medicine
Published: May 27, 2026
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 25, 2026
Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance.
Journal: The Journal of clinical investigation
Published: August 12, 2025
LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
Journal: Oncogene
Published: September 25, 2024
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: March 13, 2024
HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers.
Journal: Gene
Published: March 25, 2023
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Journal: Cell
Published: January 18, 2023
Expression of PAWR predicts prognosis of ovarian cancer.
Journal: Cancer cell international
Published: October 13, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026